Intrexon Corporation’s (XON) Outperform Rating Reiterated at JMP Securities
Intrexon Corporation (NYSE:XON)‘s stock had its “outperform” rating reiterated by investment analysts at JMP Securities in a research report issued to clients and investors on Thursday. They currently have a $42.00 price target on the biotechnology company’s stock. JMP Securities’ price target would suggest a potential upside of 111.91% from the stock’s current price.
A number of other brokerages also recently weighed in on XON. BidaskClub upgraded Intrexon Corporation from a “sell” rating to a “hold” rating in a report on Thursday, June 22nd. Zacks Investment Research downgraded Intrexon Corporation from a “hold” rating to a “sell” rating in a report on Thursday, July 13th. Finally, Northland Securities set a $30.00 price target on Intrexon Corporation and gave the company a “buy” rating in a report on Monday, August 7th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company’s stock. Intrexon Corporation has a consensus rating of “Hold” and an average target price of $41.00.
Intrexon Corporation (XON) traded up 2.88% during midday trading on Thursday, hitting $20.39. The stock had a trading volume of 697,017 shares. Intrexon Corporation has a 12-month low of $17.03 and a 12-month high of $32.90. The company’s market cap is $2.46 billion. The company has a 50-day moving average price of $18.97 and a 200-day moving average price of $21.11.
Intrexon Corporation (NYSE:XON) last issued its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.16) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.21) by $0.05. Intrexon Corporation had a negative return on equity of 19.08% and a negative net margin of 60.63%. The business had revenue of $54.40 million during the quarter, compared to the consensus estimate of $57.17 million. During the same period in the previous year, the business earned ($0.42) EPS. The business’s quarterly revenue was up 3.6% on a year-over-year basis. Equities analysts anticipate that Intrexon Corporation will post ($0.87) EPS for the current year.
WARNING: This piece was first published by American Banking News and is the property of of American Banking News. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/10/05/intrexon-corporations-xon-outperform-rating-reiterated-at-jmp-securities.html.
In related news, COO Andrew J. Last acquired 2,000 shares of the stock in a transaction that occurred on Monday, August 14th. The stock was purchased at an average cost of $19.99 per share, for a total transaction of $39,980.00. Following the purchase, the chief operating officer now directly owns 2,000 shares in the company, valued at $39,980. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Randal J. Kirk acquired 132,625 shares of the stock in a transaction that occurred on Friday, August 11th. The shares were bought at an average price of $18.85 per share, with a total value of $2,499,981.25. The disclosure for this purchase can be found here. Insiders bought a total of 144,569 shares of company stock valued at $2,719,429 over the last quarter. Company insiders own 55.10% of the company’s stock.
A number of institutional investors and hedge funds have recently modified their holdings of the stock. Dynamic Technology Lab Private Ltd bought a new position in Intrexon Corporation during the 2nd quarter worth $262,000. Raymond James Financial Services Advisors Inc. grew its stake in Intrexon Corporation by 4.4% during the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 59,146 shares of the biotechnology company’s stock worth $1,425,000 after buying an additional 2,468 shares during the last quarter. Tower Research Capital LLC TRC grew its stake in Intrexon Corporation by 2,031.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,180 shares of the biotechnology company’s stock worth $125,000 after buying an additional 4,937 shares during the last quarter. BlueCrest Capital Management Ltd bought a new position in Intrexon Corporation during the 2nd quarter worth $438,000. Finally, Gotham Asset Management LLC bought a new position in Intrexon Corporation during the 2nd quarter worth $338,000. Hedge funds and other institutional investors own 82.11% of the company’s stock.
About Intrexon Corporation
Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.
Receive News & Ratings for Intrexon Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corporation and related companies with MarketBeat.com's FREE daily email newsletter.